{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:51Z","timestamp":1786120311364,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/wnf.0b013e318241520b","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T07:33:06Z","timestamp":1325835186000},"page":"15-20","source":"Crossref","is-referenced-by-count":51,"title":["Perampanel in Parkinson Disease Fluctuations"],"prefix":"10.1097","volume":"35","author":[{"given":"Olivier","family":"Rascol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Behari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Emre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Warren","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evzen","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bibbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Squillacote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":". Review of the therapeutic management of Parkinsons disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinsons disease.","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1468-1331.2006.01548.x","article-title":". Review of the therapeutic management of Parkinsons disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinsons disease.","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(02)08520-3","article-title":". Treatment interventions for Parkinsons disease: an evidence based assessment.","volume":"359","author":"Rascol","year":"2002","journal-title":"Lancet"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":". Chronic dopaminergic stimulation in Parkinsons disease: from dyskinesias to impulse control disorders.","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurol"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinsons disease.","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurol"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinsons disease.","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":". Metabotropic glutamate receptors in the basal ganglia motor circuit.","volume":"6","author":"Conn","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.expneurol.2009.09.027","article-title":"Glutamate, excitotoxicity, and programmed cell death in Parkinson disease.","volume":"220","author":"Caudle","year":"2009","journal-title":"Exp Neurol"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0149-7634(96)00043-7","article-title":"Dopamineglutamate interactions in Parkinsons disease.","volume":"21","author":"Lange","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","article-title":"The chemical biology of clinically tolerated NMDA receptor antagonists.","volume":"97","author":"Chen","year":"2006","journal-title":"J Neurochem"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1440-1681.2008.05046.x","article-title":". Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinsons disease.","volume":"35","author":"Leaver","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainresbull.2008.08.023","article-title":". Evaluation of behavioural effects of a selective NMDA NR1A2B receptor antagonist in the unilateral 6-OHDA lesion rat model.","volume":"78","author":"Warraich","year":"2009","journal-title":"Brain Res Bull"},{"issue":"suppl 2","key":"R14-3-20210203","first-page":"II36","article-title":"Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.","volume":"247","author":"Chase","year":"2000","journal-title":"J Neurol"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ana.410300513","article-title":". The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.","volume":"30","author":"Klockgether","year":"1991","journal-title":"Ann Neurol"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/syn.1097","article-title":". LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats.","volume":"42","author":"Marin","year":"2001","journal-title":"Synapse"},{"key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":". AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/mds.22974","article-title":". Safety and efficacy of perampanel in advanced Parkinsons disease: a randomized, placebo-controlled study.","volume":"25","author":"Eggert","year":"2010","journal-title":"Mov Disord"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":". Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinico-pathological study of 100 cases.","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinsons disease: a randomised, placebo controlled, double blind, six month study.","volume":"74","author":"Brooks","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinsons disease patients. Parkinson Study Group.","volume":"42","year":"1997","journal-title":"Ann Neurol"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":". Efficacy and safety of entacapone in Parkinsons disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":". Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinsons disease.","volume":"59","author":"Kaakkola","year":"2000","journal-title":"Drugs"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":". Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mds.21894","article-title":". Placebo response in Parkinsons disease: comparisons among 11 trials covering medical and surgical interventions.","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201201000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:57Z","timestamp":1786048197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201201000-00003"}},"subtitle":["A Double-Blind Randomized Trial With Placebo and Entacapone"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318241520b","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}